Re Biosceptre International Limited

Biosceptre Australia, a biotechnology company, sought an order for a meeting of its members to consider a scheme of arrangement for the company to be redomiciled to the United Kingdom. The application was heard by Justice Bromberg in the Federal Court of Australia. The primary legal issue before the court was whether the requirements of the Corporations Act 2001 (Cth) for convening a meeting to approve the scheme had been met. The court had to determine if the Australian Securities and Investments Commission (ASIC) had had a reasonable opportunity to examine the scheme and make submissions, and if the formal requirements for convening the meeting had been satisfied. Additionally, the court needed to assess if the company's request for exemption from certain regulatory requirements was justified.

The court found that Biosceptre Australia was indeed a Part 5.1 body and the proposed scheme qualified as an arrangement under the Corporations Act. Justice Bromberg was satisfied that ASIC had been given a reasonable opportunity to examine the scheme and had chosen not to intervene. The court also determined that all formal requirements for convening the meeting were met and that the scheme, if approved, would likely be approved by the court. Furthermore, the court granted the company's request for exemption from certain regulatory requirements, finding it appropriate. The detailed submissions from senior counsel for Biosceptre Australia were deemed helpful in the court's consideration of the matter.

The court ordered that a meeting of Biosceptre Australia's members be convened to consider the scheme, with specific details on the date, location, and procedural arrangements for the meeting. The court also approved the document to be distributed to shareholders and granted exemptions from certain regulatory requirements. The proceeding was stood over for a later date to hear the application to approve the scheme.